The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

lung, and other cancers in adults. For a doctor to prescribe Enhertu, the cancer must involve HER2 in some way. Each of these cancers also has other specific criteria for treatment with Enhertu ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

ENHERTU is a specifically engineered HER2 directed ... adjuvant chemotherapy Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan ... the DESTINY-Lung01 study in HER2-positive non-small cell lung cancer (NSCLC), including an overall response rate of 55% and ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...